Maulik Nanavaty Sells 3,039 Shares of Boston Scientific Co. (BSX) Stock

Share on StockTwits

Boston Scientific Co. (NYSE:BSX) SVP Maulik Nanavaty sold 3,039 shares of Boston Scientific stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $37.81, for a total value of $114,904.59. Following the sale, the senior vice president now owns 53,299 shares of the company’s stock, valued at $2,015,235.19. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Maulik Nanavaty also recently made the following trade(s):

  • On Friday, March 15th, Maulik Nanavaty sold 3,038 shares of Boston Scientific stock. The shares were sold at an average price of $40.11, for a total value of $121,854.18.
  • On Friday, February 15th, Maulik Nanavaty sold 3,039 shares of Boston Scientific stock. The shares were sold at an average price of $40.32, for a total value of $122,532.48.

Shares of NYSE BSX opened at $34.91 on Thursday. The company has a current ratio of 0.76, a quick ratio of 0.54 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $50.29 billion, a price-to-earnings ratio of 23.75, a price-to-earnings-growth ratio of 2.21 and a beta of 0.87. Boston Scientific Co. has a 12 month low of $27.91 and a 12 month high of $41.00.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 6th. The medical equipment provider reported $0.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.02. The company had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.57 billion. Boston Scientific had a return on equity of 25.92% and a net margin of 17.01%. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.34 EPS. On average, research analysts forecast that Boston Scientific Co. will post 1.55 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on BSX shares. Zacks Investment Research downgraded Boston Scientific from a “hold” rating to a “sell” rating in a research note on Monday, December 31st. Needham & Company LLC reissued a “buy” rating and issued a $43.00 price objective on shares of Boston Scientific in a research note on Wednesday, February 6th. Canaccord Genuity cut their price objective on Boston Scientific from $45.00 to $43.00 and set a “buy” rating on the stock in a research note on Wednesday. Guggenheim reissued a “buy” rating and issued a $48.00 price objective on shares of Boston Scientific in a research note on Friday, February 8th. Finally, Argus raised their price objective on Boston Scientific from $43.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 13th. Three equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and two have given a strong buy rating to the company. Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $40.72.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC increased its position in Boston Scientific by 1.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 404,011 shares of the medical equipment provider’s stock worth $15,506,000 after buying an additional 6,410 shares during the period. Northpointe Capital LLC bought a new stake in shares of Boston Scientific during the first quarter valued at approximately $2,409,000. Flagship Harbor Advisors LLC increased its position in shares of Boston Scientific by 15.7% during the first quarter. Flagship Harbor Advisors LLC now owns 20,898 shares of the medical equipment provider’s stock valued at $802,000 after purchasing an additional 2,830 shares during the period. Ropes Wealth Advisors LLC increased its position in shares of Boston Scientific by 153.7% during the first quarter. Ropes Wealth Advisors LLC now owns 1,522 shares of the medical equipment provider’s stock valued at $58,000 after purchasing an additional 922 shares during the period. Finally, Retirement Systems of Alabama increased its position in shares of Boston Scientific by 0.6% during the first quarter. Retirement Systems of Alabama now owns 1,317,267 shares of the medical equipment provider’s stock valued at $50,557,000 after purchasing an additional 7,618 shares during the period. 91.70% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Maulik Nanavaty Sells 3,039 Shares of Boston Scientific Co. (BSX) Stock” was originally posted by Macon Daily and is owned by of Macon Daily. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://macondaily.com/2019/04/18/maulik-nanavaty-sells-3039-shares-of-boston-scientific-co-bsx-stock-2.html.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Further Reading: Marijuana Stocks Future Looks Bright

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.